Ionis holder plans Rule 144 sale of 15,642 shares
Ionis Pharmaceuticals shareholder Eric Swayze has filed a notice of proposed sale of 15,642 shares of common stock under Rule 144.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Ionis Pharmaceuticals shareholder Eric Swayze has filed a notice of proposed sale of 15,642 shares of common stock under Rule 144. The shares, to be sold through Stifel Nicolaus & Company Inc. on Nasdaq around 02/13/2026, have an aggregate market value of $1,277,169.00. The filing notes that 161,974,393 shares of Ionis common stock were outstanding. These 15,642 shares were acquired on 01/15/2026 as restricted stock units granted by the issuer as equity compensation. Over the prior three months, Swayze sold additional Ionis common stock in three transactions totaling 39,526 shares for gross proceeds of $3,122, - combining reported amounts of $1,853,577.00, $753,501.00, and $512,906.00.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does the Form 144 filing for Ionis (IONS) disclose?
What recent Ionis (IONS) stock sales has Eric Swayze reported in the last 3 months?
AI-generated analysis. How Rhea-AI works. Not financial advice.